Patients with diabetes have poor control of risk factors for vascular disease

January 20, 2004

Despite recommendations on the importance of controlling risk factors such as blood pressure, glucose levels and cholesterol levels for preventing vascular disease, only seven percent of patients with diabetes control these factors as needed, according to a study in the January 21 issue of The Journal of the American Medical Association (JAMA).

Individuals with diagnosed diabetes are at an increased risk for vascular disease (involving the blood vessels and circulation), including microvascular complications (e.g., retinopathy, neuropathy, and nephropathy) and macrovascular complications (e.g., coronary heart disease and stroke), and lower extremity amputations, according to information in the article. Compelling evidence from well-designed, randomized clinical trials demonstrates that control of blood glucose levels, blood pressure, and cholesterol levels can delay or prevent the microvascular and macrovascular complications of diabetes.

Sharon H. Saydah, Ph.D., of the U.S. Centers for Disease Control and Prevention, Hyattsville, Md., and colleagues examined trends in control of risk factors for vascular disease among adults with diagnosed diabetes in the United States over nearly a decade. The researchers used data from two national health surveys: the Third National Health and Nutrition Examination Survey (NHANES III) conducted from 1988-1994 and the NHANES 1999-2000.

The researchers compared levels of glycosylated hemoglobin (HbA1c, a measure of how well blood glucose levels are controlled), blood pressure, and total serum cholesterol among adults aged 20 years and older with previously diagnosed diabetes who participated in both the interview and examination in either NHANES III (n=1,265) or NHANES 1999-2000 (n=441).

The researchers found that in NHANES 1999-2000, only 37.0 percent of participants achieved the target goal of HbA1c level less than 7.0 percent and 37.2 percent of participants were above the recommended "take action" HbA1c level of greater than 8.0 percent; these percentages did not change significantly from NHANES III. "Only 35.8 percent of participants achieved the target of systolic blood pressure (SBP) less than 130 mm Hg and diastolic (DBP) less than 80 mm Hg, and 40.4 percent had hypertensive blood pressure levels (SBP 140 or greater or DBP 90 mm Hg or greater). These percentages did not change significantly from NHANES III. Over half (51.8 percent) of the participants in NHANES 1999-2000 had total cholesterol levels of 200 mg/dL or greater (vs. 66.1 percent in NHANES III). In total, only 7.3 percent of adults with diabetes in NHANES 1999-2000 attained recommended goals of HbA1c level less than 7 percent, blood pressure less than 130/80 mm Hg, and total cholesterol level less than 200 mg/dL," the authors write.

"... further measures are needed to reduce the large proportion of adults with diagnosed diabetes in the United States who continue to have high levels of blood glucose, blood pressure, and total cholesterol. Ongoing monitoring and measurement of the quality of care, empowering clinicians with medical decision-support tools and patients with information to improve the quality of care they receive, and building incentives for providing comprehensive care into the health care delivery system are essential to translating into practice the therapies that have been proven effective in reducing the risk of vascular disease in individuals with diabetes," the authors conclude.
(JAMA. 2004;291:335-342. Available post-embargo at

Editor's Note: The National Institute of Diabetes and Digestive and Kidney Diseases funded portions of the data collected in the NHANES III and NHANES 1999-2000. Dr. Saydah was an employee of Social and Scientific Systems Inc. during the completion of this work, under a contract from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

The JAMA Network Journals

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to